Top-Rated StocksTop-RatedNASDAQ:CYTK Cytokinetics (CYTK) Stock Price, News & Analysis → AI “wealth window” is closing June 25th (From Paradigm Press) (Ad) Free CYTK Stock Alerts $65.84 +0.79 (+1.21%) (As of 11:52 AM ET) Add Compare Share Share Today's Range$64.53▼$66.5250-Day Range$61.32▼$80.9952-Week Range$25.98▼$110.25Volume200,378 shsAverage Volume2.75 million shsMarket Capitalization$6.89 billionP/E RatioN/ADividend YieldN/APrice Target$79.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Cytokinetics alerts: Email Address Cytokinetics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.87 Rating ScoreUpside/Downside22.1% Upside$79.33 Price TargetShort InterestBearish13.91% of Float Sold ShortDividend StrengthN/ASustainability-0.83Upright™ Environmental ScoreNews Sentiment0.64Based on 7 Articles This WeekInsider TradingSelling Shares$5.69 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($4.50) to ($3.28) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.70 out of 5 starsMedical Sector261st out of 903 stocksPharmaceutical Preparations Industry117th out of 420 stocks 3.4 Analyst's Opinion Consensus RatingCytokinetics has received a consensus rating of Moderate Buy. The company's average rating score is 2.87, and is based on 13 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageCytokinetics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted13.91% of the float of Cytokinetics has been sold short.Short Interest Ratio / Days to CoverCytokinetics has a short interest ratio ("days to cover") of 6.9.Change versus previous monthShort interest in Cytokinetics has recently increased by 6.12%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCytokinetics does not currently pay a dividend.Dividend GrowthCytokinetics does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCytokinetics has received a 71.40% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Preclinical research services for physical health", "Clinical research services for physiological diseases ", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Cytokinetics is -0.83. Previous Next 2.6 News and Social Media Coverage News SentimentCytokinetics has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.40 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Cytokinetics this week, compared to 6 articles on an average week.Search InterestOnly 6 people have searched for CYTK on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Cytokinetics to their MarketBeat watchlist in the last 30 days. This is a decrease of -71% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cytokinetics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,689,675.00 in company stock.Percentage Held by InsidersOnly 3.40% of the stock of Cytokinetics is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Cytokinetics are expected to grow in the coming year, from ($4.50) to ($3.28) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cytokinetics is -11.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cytokinetics is -11.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Colonial MetalsThe Gold Grab of the CenturyWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.That's why we have released our Free Precious Metals Investment Guide. About Cytokinetics Stock (NASDAQ:CYTK)Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.Read More CYTK Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CYTK Stock News HeadlinesApril 26, 2024 | insidertrades.comJohn T. Henderson Sells 10,562 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) StockApril 10, 2024 | insidertrades.comCytokinetics, Incorporated (NASDAQ:CYTK) EVP Sells $2,422,877.55 in StockMay 7, 2024 | DTI (Ad)The best inflation-proof investment The markets are CRAZY right now. Which is why thousands of investors are flocking into one little-known company. May 2, 2024 | globenewswire.comCytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 2, 2024 | americanbankingnews.comCytokinetics, Incorporated (NASDAQ:CYTK) Short Interest Up 6.1% in AprilMay 1, 2024 | benzinga.com(CYTK) - Analyzing Cytokinetics's Short InterestApril 29, 2024 | globenewswire.comCytokinetics to Host Investor Event and Conference Call to Discuss the Primary Results From SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 CongressApril 28, 2024 | barrons.comCytokinetics Inc.May 7, 2024 | DTI (Ad)The best inflation-proof investment The markets are CRAZY right now. Which is why thousands of investors are flocking into one little-known company. April 28, 2024 | nasdaq.comJune 7th Options Now Available For Cytokinetics (CYTK)April 27, 2024 | americanbankingnews.comCytokinetics, Incorporated (NASDAQ:CYTK) Given Consensus Rating of "Moderate Buy" by BrokeragesApril 26, 2024 | marketwatch.comCytokinetics Taps Sung Lee as Permanent CFOApril 24, 2024 | globenewswire.comCytokinetics to Announce First Quarter Results on May 8, 2024April 11, 2024 | uk.investing.comCytokinetics to present phase 3 trial results for heart drug at Heart Failure 2024April 11, 2024 | uk.investing.comCytokinetics EVP sells over $2.4m in company stockApril 10, 2024 | globenewswire.comCytokinetics Announces Three Late Breaking Clinical Trial Presentations Relating to SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 CongressApril 10, 2024 | globenewswire.comCytokinetics Announces Three Late Breaking Clinical Trial Presentations Relating to SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 CongressApril 9, 2024 | finance.yahoo.comEVP Research & Development Fady Malik Sells Shares of Cytokinetics Inc (CYTK)April 5, 2024 | markets.businessinsider.comBuy Rating Affirmed for Cytokinetics Amid Strong Aficamten Trial ResultsApril 5, 2024 | markets.businessinsider.comBuy Rating Affirmed on Cytokinetics Amid Promising Aficamten Clinical ResultsApril 5, 2024 | globenewswire.comCytokinetics Presents Additional 48-Week Data From FOREST-HCM, the Open Label Extension Clinical Study of Aficamten, at The American College of Cardiology 73ʳᵈ Annual Scientific SessionApril 3, 2024 | benzinga.com$100 Invested In Cytokinetics 5 Years Ago Would Be Worth This Much TodayApril 2, 2024 | globenewswire.comCytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 1, 2024 | globenewswire.comCytokinetics to Participate in the 23rd Annual Needham Virtual Healthcare ConferenceApril 1, 2024 | seekingalpha.comCytokinetics, Incorporated: Buyout Speculation PersistsMarch 30, 2024 | finance.yahoo.comCYTK Apr 2024 60.000 callMarch 27, 2024 | msn.comCytokinetics gains amid renewed takeover speculationSee More Headlines Receive CYTK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cytokinetics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/27/2024Today5/07/2024Next Earnings (Confirmed)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CYTK CUSIPN/A CIK1061983 Webwww.cytokinetics.com Phone(650) 624-3000Fax650-624-3010Employees423Year Founded1997Price Target and Rating Average Stock Price Target$79.33 High Stock Price Target$108.00 Low Stock Price Target$50.00 Potential Upside/Downside+22.0%Consensus RatingModerate Buy Rating Score (0-4)2.87 Research Coverage15 Analysts Profitability EPS (Most Recent Fiscal Year)($5.45) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-526,240,000.00 Net Margins-6,988.63% Pretax Margin-6,988.63% Return on EquityN/A Return on Assets-65.08% Debt Debt-to-Equity RatioN/A Current Ratio6.12 Quick Ratio6.12 Sales & Book Value Annual Sales$7.53 million Price / Sales903.44 Cash FlowN/A Price / Cash FlowN/A Book Value($3.94) per share Price / Book-16.51Miscellaneous Outstanding Shares104,580,000Free Float101,020,000Market Cap$6.80 billion OptionableOptionable Beta0.72 Social Links 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. Robert I. Blum (Age 60)CEO, President, Principal Financial Officer & Director Comp: $1.33MMr. Robert C. Wong (Age 56)VP & Chief Accounting Officer Comp: $495.72kDr. Fady Ibraham Malik FACC (Age 60)M.D., Ph.D., Executive Vice President of Research & Development Comp: $839.66kMr. Andrew M. Callos (Age 55)Executive VP & Chief Commercial Officer Comp: $752.84kDr. James A. Spudich Ph.D. (Age 82)Co-Founder & Member of Scientific Advisory Board Comp: $21.94kMr. Jeff LotzVice President of Sales & OperationsMr. Matt YangVice President of Corporate Finance and Financial Planning & AnalysisMr. Steven M. Cook (Age 65)Senior Vice President of Global Supply Chain Operations & Technical Operations Ms. Kari K. Loeser J.D.VP & Chief Compliance OfficerMr. John O. Faurescu Esq.VP, Associate General Counsel & Corporate SecretaryMore ExecutivesKey CompetitorsElanco Animal HealthNYSE:ELANIonis PharmaceuticalsNASDAQ:IONSIntra-Cellular TherapiesNASDAQ:ITCIJazz PharmaceuticalsNASDAQ:JAZZBlueprint MedicinesNASDAQ:BPMCView All CompetitorsInsiders & InstitutionsLisanti Capital Growth LLCSold 32,675 shares on 5/7/2024Ownership: 0.017%Oppenheimer & Co. Inc.Bought 5,158 shares on 5/7/2024Ownership: 0.008%ClariVest Asset Management LLCBought 5,086 shares on 5/7/2024Ownership: 0.005%Texas Permanent School Fund CorpBought 1,111 shares on 5/6/2024Ownership: 0.082%Mutual of America Capital Management LLCBought 41,275 shares on 5/2/2024Ownership: 0.056%View All Insider TransactionsView All Institutional Transactions CYTK Stock Analysis - Frequently Asked Questions Should I buy or sell Cytokinetics stock right now? 15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cytokinetics in the last twelve months. There are currently 2 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" CYTK shares. View CYTK analyst ratings or view top-rated stocks. What is Cytokinetics' stock price target for 2024? 15 equities research analysts have issued 12-month price targets for Cytokinetics' shares. Their CYTK share price targets range from $50.00 to $108.00. On average, they predict the company's share price to reach $79.33 in the next year. This suggests a possible upside of 22.1% from the stock's current price. View analysts price targets for CYTK or view top-rated stocks among Wall Street analysts. How have CYTK shares performed in 2024? Cytokinetics' stock was trading at $83.49 at the beginning of the year. Since then, CYTK shares have decreased by 22.2% and is now trading at $64.95. View the best growth stocks for 2024 here. Are investors shorting Cytokinetics? Cytokinetics saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 14,040,000 shares, an increase of 6.1% from the March 31st total of 13,230,000 shares. Based on an average daily trading volume, of 2,030,000 shares, the days-to-cover ratio is currently 6.9 days. Currently, 13.9% of the company's shares are short sold. View Cytokinetics' Short Interest. When is Cytokinetics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our CYTK earnings forecast. How can I listen to Cytokinetics' earnings call? Cytokinetics will be holding an earnings conference call on Wednesday, May 8th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link. How were Cytokinetics' earnings last quarter? Cytokinetics, Incorporated (NASDAQ:CYTK) announced its earnings results on Tuesday, February, 27th. The biopharmaceutical company reported ($1.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.03) by $0.35. The biopharmaceutical company earned $1.70 million during the quarter, compared to analysts' expectations of $7.62 million. The company's revenue for the quarter was down 10.5% compared to the same quarter last year. During the same period in the prior year, the company earned ($1.45) earnings per share. What ETFs hold Cytokinetics' stock? ETFs with the largest weight of Cytokinetics (NASDAQ:CYTK) stock in their portfolio include Tema Cardiovascular and Metabolics ETF (HRTS), Fidelity Disruptive Medicine ETF (FMED), Principal Healthcare Innovators ETF (BTEC), Virtus LifeSci Biotech Clinical Trials ETF (BBC), SPDR S&P Biotech ETF (XBI), VanEck Biotech ETF (BBH), Invesco Nasdaq Biotechnology ETF (IBBQ) and BNY Mellon Innovators ETF (BKIV). What guidance has Cytokinetics issued on next quarter's earnings? Cytokinetics issued an update on its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $3.0 million-$5.0 million, compared to the consensus revenue estimate of $28.5 million. What is Robert I. Blum's approval rating as Cytokinetics' CEO? 16 employees have rated Cytokinetics Chief Executive Officer Robert I. Blum on Glassdoor.com. Robert I. Blum has an approval rating of 64% among the company's employees. What other stocks do shareholders of Cytokinetics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cytokinetics investors own include XOMA (XOMA), Arena Pharmaceuticals (ARNA), OncoSec Medical (ONCS), Novavax (NVAX), Amgen (AMGN), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), TherapeuticsMD (TXMD) and Gilead Sciences (GILD). Who are Cytokinetics' major shareholders? Cytokinetics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Principal Financial Group Inc. (0.41%), Pinnacle Associates Ltd. (0.25%), BNP Paribas Financial Markets (0.16%), Peregrine Capital Management LLC (0.12%), Retirement Systems of Alabama (0.12%) and New York State Teachers Retirement System (0.11%). Insiders that own company stock include B Lynne Parshall, Ching Jaw, David Cragg, Edward M Md Kaye, Fady Ibraham Malik, John T Henderson, L Patrick Gage, Mark A Schlossberg, Muna Bhanji, Robert I Blum, Robert I Blum, Robert Wong, Sandford D Smith, Santo J Costa and Wendall Wierenga. View institutional ownership trends. How do I buy shares of Cytokinetics? Shares of CYTK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CYTK) was last updated on 5/7/2024 by MarketBeat.com Staff From Our PartnersThe #1 lithium battery stock to have on your radar in 2024!Smallcaps DailyThe best inflation-proof investment DTIAI “wealth window” is closing June 25thParadigm PressThe asset beating inflation by 4xColonial MetalsCould Your Accounts Be Frozen?Allegiance GoldHe Is Giving Away BitcoinCrypto Swap ProfitsElon Musk Secret Crypto Plot ExposedCrypto 101 MediaElon to Transform U.S. Economy? Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cytokinetics, Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
